We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for durvalumab (AstraZeneca Pty Ltd)
Active ingredients
durvalumab
Sponsor
Date of review outcome
Lapse date
Type
Priority review
Indication
Treatment of patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following platin-based chemoradiation therapy
Therapeutic area
Oncology